Therefore, we can conclude that D#22 cells are potentially a more useful cell source for β-cell replacement therapy in diabetes than iPS cells because the former are safer and capable of generating greater numbers of functional insulin-producing cells. This evidence concerns the gene INS and diabetes mellitus.